Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Essential services: Quantifying the contributions of America’s pharmacists in COVID-19 clinical interventions

John D. Grabenstein*
Key Points

Background:

- America’s pharmacists and their teammates provided COVID-19 interventions from every practice setting, including community and ambulatory care, inpatient, long-term care, academia, and public health.
- These interventions span the gamut of diagnosis, prevention, treatment, and support.

Findings:

- A total of >270 million COVID-19 vaccinations (45% of U.S. total) given by community pharmacists and teams, overall >50% via pharmacist-led programs, Dec 2020—Sep 2022.
- A total of >42 million patient specimens tested by pharmacists for COVID-19, Apr 2020—Jul 2022.
- A total of >100,000 COVID-19 monoclonal antibody treatments provided by pharmacists, Nov 2020—Jun 2022.

Both independent pharmacies and national and regional chains of traditional drug stores and mass merchants and grocery stores with pharmacies, ambulatory-care clinics, bedrock community hospitals, major research hospitals, federal facilities (e.g., Veterans Affairs [VA], Department of Defense [DoD], and Indian Health Service [IHS]), nursing homes, assisted-living communities, community-based clinics, colleges, health departments, and military units. When that was not enough, countless pharmacists’ teams packed up mobile units with kits and coolers and traveled to where they could reach even more people: arenas, sports stadiums, community centers, schools, rural outposts, houses of worship, and wherever people congregate.

The contributions of America’s pharmacists and teammates have been myriad, spanning the gamut of diagnosis, prevention, treatment, and support. Pharmacists’ teams used a remarkable variety of tools to keep people healthy or help them recover from COVID-19: primary vaccinations, booster vaccinations, diagnostic tests, convalescent plasma, monoclonal antibodies, antiviral medications, and supportive therapies. They injected, they swabbed, they tested, they provided, they prescribed, they dispensed, they coached, they taught, they explained, they listened, they explained some more. Often, pharmacists reached where few others could, crossing vast distances and crossing cultural or linguistic divides to reach disadvantaged communities.

Methods

Statistics on clinical interventions were gathered from April 2022 through September 2022 from publications and web pages of federal agencies describing authorization and distribution of COVID-19 medical countermeasures, including those of U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Government Accountability Office (GAO), and the Department of Health and Human Services (DHHS). Literature published in professional journals was also searched using terms such as (COVID-19 and (pharmacist) and (plasma or monoclonal or vaccine or antiviral)). Reference lists were scanned for other relevant documents. Additional input was sought through queries to senior leaders of the constituent organizations (Academy of Managed Care Pharmacy, American Association of Colleges of Pharmacy, American College of Apothecaries, American College of Clinical Pharmacy, Accreditation Council for Pharmacy Education, American Pharmacists Association, American Society of Consultant Pharmacists, American Society of Health-System Pharmacists, College of Psychiatric/Neuologic Pharmacists, Hematology/Oncology Pharmacy Association, National Association of Boards of Pharmacy, National Community Pharmacists Association, National Alliance of State Pharmacy Associations) of the Joint Commission of Pharmacy Practitioners (jcpp.net), other relevant stakeholders, and searches of their organizations’ websites. Findings related to educational efforts and program advocacy were considered out of scope.

Spring 2020: COVID-19 pandemic spreads across America

In December 2019 and early 2020, stories about severe pneumonia cases following coronavirus infection filled the news, an outbreak spreading from Wuhan, Hubei province,
China. Attempts to contain the virus failed, and it spread worldwide. The World Health Organization declared a Public Health Emergency of International Concern on January 30, 2020, and a global pandemic on March 11, 2020.

The first U.S. cases were diagnosed in mid-January 2020. On January 31, 2020, the DHHS Secretary declared a public health emergency for the entire United States to aid in the response of the health care community to the COVID-19 outbreak. On March 1, 2020, the President declared that the COVID-19 outbreak in the United States constituted a national emergency. On March 10, 2020, the Secretary issued a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to enable distribution of specific medical countermeasures against COVID-19, with several amendments and clarifications issued since then.

As March 2020 arrived, nature proceeded in its usual springtime patterns, but human societal patterns across America were already seriously disrupted. The virus spread widely, hospitals filled and overflowed, and supply shortages began to manifest. Outpatient medical visit patterns were severely disrupted. The first imperative for pharmacists was to continue providing prescription medications, therapy management, and consulting services for hundreds of millions of Americans each week. Pharmacists hastened to require extra distance between an increased volume of clients, arrange plexiglass barriers, and protect inventory. They moved scarce hand sanitizer, alcohol swabs, masks, thermometers, sterile water (for sleep-apnea devices), and other products behind the pharmacy counter to preclude hoarding.

On a typical pre-pandemic day, America’s pharmacists dispensed 17 million outpatient prescriptions, cared for 1 million inpatients,11 and provided medications and advice for COVID-19 and hundreds of millions seeking protection from other practices to meet their neighbors’ changing needs and circumstances.13-21 Pharmacists dealt with unexpected medication and supply shortages, patient access challenges, and staffing disruptions as workers contracted COVID-19 or were quarantined after contact with a confirmed infected patient. Multiple anticoagulation, hypertension, osteoporosis, and other clinical care interventions shifted to drive-through and other innovative venues beyond a pharmacy’s 4 walls.17 Pharmacy teams used technology to enable teleconsultations (i.e., telehealth). Interventions for antimicrobial stewardship were a common need.22 In the case of hydroxychloroquine and ivermectin, pharmacists helped protect against limitations on these investigational agents (24%), and dialysis solutions (6%). Medication-use changes were implemented by 86% of hospitals, most commonly involving guidelines for COVID-19 treatment (79%) and opening compassionate use or investigational drug studies (55%). Shortages of personal protective equipment and other basic supplies compounded the struggle to continue care delivery.

When health systems created ad hoc facilities to provide care during patient surges, their pharmacists’ teams created the requisite alternate care site pharmacies.23 Similar experiences occurred in cities across the country.24-30 In long-term care settings, procedures to reduce resident-staff contacts by reducing medication burden (i.e., number of medications and associated bedside encounters) were adopted.31-33

Managing shortages amid workflow disruption was a recurring theme. Consistently since March 2020, as each new clinical intervention became available (e.g., diagnostic test, antibody product, vaccine, antiviral), there was insufficient supply for the entire country all at once. Time after time, pharmacists helped triage which patients were most likely to benefit from any given product until manufacturing pipelines could increase their output.34,35

COVID-19 testing

On February 4, 2020, FDA issued the first emergency use authorization (EUA) for an in vitro diagnostic test to detect or diagnose COVID-19.35,36 By late March 2020, the manufacturing pipeline was producing steadily increasing numbers of tests, allowing distribution across the country. Recognizing the value of rapid diagnosis and the proximity of pharmacists to the American population—90% live within 5 miles of a community pharmacy.37-40—the Secretary of DHHS authorized pharmacists to order and administer FDA-approved COVID-19 tests on April 8, 2020.

During the 2010s, community pharmacists were growing steadily as providers of tests waived from requirements of the Clinical Laboratory Improvement Amendments (CLIA) of 1988.41 With the pandemic, pharmacists became increasingly common sources for people to access CLIA-waived tests. According to statistics compiled by the National Alliance of State Pharmacy Associations, an additional number of 14,522 CLIA waivers were granted to pharmacies between May 2020 and May 2022 (27,091 in total).

In April 2020, the DHHS formed a partnership with community pharmacies for pharmacist-based COVID-19 testing, integrating pharmacists into the Community-Based Testing Sites (CBTS) program, beginning with 362 sites across 45 states and the District of Columbia (DC).37,41-43 The pharmacist-based components of the program grew rapidly:

- April 2020: 362 sites in 45 states and DC
- June 2020: 623 sites in 48 states, DC, and Puerto Rico (PR); >700,000 samples tested (cumulative)
- January 2021: 3300 sites in 50 states, DC, and PR; >5.6 million samples tested
- March 2021: 6211 sites in 50 states, DC, and PR; >9.8 million samples tested

In January 2021, the DHHS highlighted that more than 70% of pharmacy sites within the CBTS program were located in communities with moderate-to-high social vulnerability.37,46
In April 2021, the CBTS program transitioned into the Increasing Community Access to Testing (ICATT) for COVID-19 program. The CDC reports that more than 10,000 pharmacy sites participate in ICATT. These locations performed more than 42 million COVID-19 tests from April 2020 through July 2022, receiving high marks for satisfaction from their patients.

Convalescent plasma

Passive immunization, using preformed antibodies to prevent or ameliorate infection, has been used for more than a century against various microbial pathogens. The SARS-CoV-2 virus was untreatable in spring 2020 except to manage symptoms. Therefore, clinicians logically turned to plasma from patients convalescing after COVID-19 disease, expecting it to be a rich source of antibodies to neutralize the SARS-CoV-2 virus.

Pharmacists in many hospitals contributed to multidisciplinary efforts to recruit plasma donors, harvest and process the plasma, and administer it to eligible patients. Eventually, Expanded Access Protocols (EAPs) for COVID-19 convalescent plasma encompassed more than 2700 hospitals through August 2020. The EAPs were succeeded by an EUA issued by FDA on August 23, 2020.

Although a meta-analysis of multiple clinical trials of COVID-19 convalescent plasma suggested some reduction in risk of death among hospitalized COVID-19 patients, issues related to prompt intervention, identification of high-titer plasma units, donor solicitation and screening, and regulatory hurdles, among others, limited the utility of this approach. Availability of specific monoclonal antibody products from November 2020 onward offered therapeutic products in ready-to-use formulations with more standardized potency and a clearer basis of evidence.

Monoclonal antibody treatments

FDA issued EUAs for Lilly’s bamlanivimab and Regeneron’s casirivimab with imdevimab (also called REGEN-COV) on November 9 and 21, 2020, respectively, for certain adult and pediatric patients at elevated risk for progressing to severe COVID-19. Both products comprised monoclonal antibodies administered by intravenous (I.V.) infusion. The U.S. Government purchased 950,000 doses of bamlanivimab and nearly 3 million doses of casirivimab/imdevimab between July 2020 and September 2021, although it is unclear how many of these doses were administered.

FDA issued EUAs for other monoclonal antibody products as the months went by:

- February 9, 2021: Bamlanivimab/etesevimab (Lilly), I.V. infusion. Purchases: 388,000 doses (September 2021)
- May 26, 2021: Sotrovimab (Xevudy, GlaxoSmithKline with Vir), I.V. infusion, later intramuscular (I.M.) injection. Purchases: 1 million doses (November 2021-January 2022)
- December 8, 2021: Tixagevimab/cilgavimab (Evusheld, AstraZeneca), I.M. injection. Purchases: 1.7 million doses (December 2021-February 2022)

Pharmacists at most U.S. hospitals quickly engaged in patient selection, counseling, administration, monitoring, and other clinical services. A pharmacist at the University of Pittsburgh Medical Center helped demonstrate the utility of administering casirivimab/imdevimab as a set of...
4 subcutaneous injections and led monoclonal treatments for more than 22,000 patients.63,64

In September 2021, anticipating the approach of influenza season, the DHHS Secretary issued the ninth amendment to the medical countermeasures declaration to authorize pharmacists to both order and administer certain COVID-19 therapeutics (Table 1). Several states, including Arkansas, Mississippi, and Oregon, responded quickly, implementing statewide standing orders or protocols to allow pharmacists to independently order and administer casirivimab/imdevimab COVID-19 monoclonal antibodies. The Society of Infectious Diseases Pharmacists developed a toolkit informed by the experiences of pharmacists who implemented monoclonal antibody programs at their institutions for treatment, post-exposure prophylaxis, and pre-exposure prophylaxis.67

Unfortunately, the SARS-COV-2 virus did not stand still, neither geographically nor antigenically. Genetic mutations produced viral variants that were no longer adequately neutralized by hyperspecific monoclonal antibodies. At various times in January and April 2022, FDA notified clinicians that due to the high frequency of certain variants, casirivimab/imdevimab, bamlanivimab/etesevimab, and sotrovimab were no longer authorized in any U.S. region, until further notice by FDA.68 This situation will likely remain fluid.

The American Pharmacists Association (APhA) created tools to help pharmacists refer eligible patients to infusion centers to receive monoclonal antibody products administered by I.V. infusion.69 Health-system pharmacists staffed many of those infusion centers.69,70 Later, products amenable to subcutaneous or intramuscular injection were suitable for administration by outpatient providers, including pharmacists. Pharmacists administered monoclonal antibodies in community, inpatient, and nursing home settings. An Arkansas pharmacist who treated more than 300 patients this way reported that her patients had often been placed on waiting lists at hospitals near their homes but were able to receive the medication conveniently in her community practice.71

December 2020: vaccine doses begin flowing

Research efforts to produce COVID-19 vaccines initiated in spring 2020 started to look promising as fall 2020 arrived. The eventual unprecedented success of these efforts was due in large part to pre-pandemic work with other human coronavirus vaccine candidates, exploration of mRNA vaccine approaches dating back 15 years, the federal government taking the financial risk in case clinical trials did not succeed, manufacturers performing many of the required development steps simultaneously (rather than in sequence), and the willingness of many tens of thousands of people to volunteer for clinical trials quickly.

Finally, in December 2020, America’s ability to control the pandemic took a dramatic turn for the better. FDA granted EUA status to messenger ribonucleic acid (mRNA) vaccines manufactured by Pfizer-BioNTech and by Moderna.72 The CDC’s Advisory Committee on Immunization Practices (ACIP) swiftly recommended the products for widespread use in a phased manner, according to degree of disease risk, as vaccine manufacturing delivered steadily increasing quantities of vaccine.73 Ultra-cold storage temperatures posed special logistical requirements and challenges.

Fortunately, the DHHS and CDC had been planning to include pharmacies and pharmacists in pandemic responses, increasingly since the 2009 influenza A/H1N1 response.75,77-79 In September 2020, the DHHS and CDC started reaching out to pharmacy associations and pharmacy businesses to gauge interest and begin planning large-scale, widely dispersed COVID-19 vaccination programs within pharmacies, as well as having pharmacists administer vaccines in other venues.77

Federal pharmacy partnership for long-term care program

At the top of the priority list for COVID-19 vaccination were residents and staff of LTC facilities, such as nursing homes and skilled nursing facilities. For decades, pharmacists and pharmacies have had consulting relationships with these facilities, so that they already were providing personalized medications and supplies for residents, monthly medication therapy reviews (i.e., drug utilization reviews), and other clinical services. In the first few months of COVID-19 vaccine availability, pharmacists were the most frequent vaccinators at these facilities.

The CDC established the Federal Pharmacy Partnership for Long-Term Care Program in October 2020, an agreement with CVS, Walgreens, and Managed Health Care Associates Inc (a group purchasing organization and pharmacy services administrative organization [PSAO] serving independent LTC pharmacies) to ship and administer COVID-19 vaccines to residents and staff of LTC facilities.80-83 These partners provided 8.1 million on-site vaccinations for residents and staff at more than 62,000 LTC and assisted-living facilities from December 21, 2020, until April 23, 2021, when the program was consolidated with the Federal Retail Pharmacy Program (FRPP).84

In mid-December 2020, the federal government provided most of the limited supply of vaccine doses to states and jurisdictions and began shipping vaccine to selected pharmacies serving residents and staff in LTC facilities. In mid-January 2021, the CDC issued funding and guidance for all jurisdictions and included as its first recommendation to jurisdictions “increase the number of vaccine provider sites, including through the use of pharmacies.”

A graph of deaths of nursing-home residents over time published on the front page of the New York Times in late February 2021 looks like a waterfall85 (Figure 1), illustrating both the high degree of efficacy of the first mRNA vaccines and the promptness with which providers, especially pharmacists, delivered the vaccines to LTC residents.86

West Virginia followed a different path than other states for its LTC residents and staff, empowering independent pharmacies with teams who knew the many rural sites across the Mountain State. The West Virginia program was set up promptly, and their pharmacists completed its first round of nursing home vaccination clinics before the end of December 2020, faster than any other state.86-91 West Virginia’s nearly 250 independent pharmacies administered 28,000 first doses to residents and staff members in 210 LTC facilities, making West Virginia the first state to offer vaccination to all nursing-home residents. These local pharmacists used existing relationships with nursing homes to gather information and leveraged the trust of patients in encouraging them to get vaccinated.
When vaccine was so scarce in the first few months of vaccinating, pharmacists helped quantify the amount of vaccine intentionally overfilled into each vial.92-95 Overfill is the quantity of vaccine intentionally placed into each vial to assure that the minimum quantity retrievable with syringe and needle does not fall below the number of doses specified on the product labeling. Specific syringe-needle combinations with tight fittings and reduced “dead space” minimized retained fluid that could not be injected. Variability in the syringes provided with vaccine shipments made this challenging to predict. Pharmacists asked to use their aseptic compounding skills to avoid wasting those doses. FDA eventually agreed. These efforts by pharmacists expanded that initial scarce vaccine supply by 10%-20%.

Federal government partners with the community pharmacy

In November 2020, the DHHS released its first list of participating pharmacy organizations in what would come to be known as the FRPP for COVID-19 vaccination. This list primarily included pharmacy chains with large numbers of outlets. These chains had been planning and modeling with federal planners increasingly since 2009 to forge public-private partnerships that enabled rapid roll-out of COVID-19 vaccinations from December 2020 onward. Additional partners were included, particularly independent pharmacies networked through wholesaler-based PSAOs. In January 2021, the White House released updated vaccination plans featuring community pharmacies as prominent providers of COVID-19 vaccines,74,76 to expand access to COVID-19 vaccines for the American people. This program developed into a partnership with 21 national pharmacy chains, independent pharmacy networks, and LTC pharmacists96 (Table 2), offering COVID-19 vaccinations at more than 41,000 community and LTC pharmacy locations across the country. Vaccine distribution through this channel began on February 9, 2021. In addition to the FRPP, state and local jurisdictions directly engaged additional pharmacies not enrolled in the FRPP, as well as FRPP-enrolled pharmacies to expand access and meet specific community needs.

The Federal Transfer Program with Jurisdiction(s) for COVID-19 Vaccination allowed states to transfer allocated vaccine doses to federal pharmacy partners to minimize vaccine wastage, as an interim solution as the FRPP took shape. At least 7 pharmacy chains participated in this program.37

As spring 2021 proceeded, the supply of vaccine was expanding, and vaccinations no longer needed to be centralized to a few large mass-vaccination sites. Mass-vaccination sites administered 5.6 million doses between February and June 2021, when most were disbanded.84 In April 2021, the CDC issued further guidance and funding to jurisdictions urging them to “improve access to COVID-19 vaccines” by “using multiple types of locations and with flexible hours that are accessible to and frequented by the identified communities of focus” including pharmacies. As expanding supply enabled distribution to more sites, the proportion of vaccine doses distributed through the CDC’s FRPP increased.

Between mid-December 2020 and September 2022, pharmacists’ teams administered more than 270 million doses of the COVID-19 vaccine. These doses include 8.1 million doses administered on site at LTC facilities.84,96,97 During this interval, the total number of COVID-19 vaccinations reported across

**Figure 1.** Proportion of weekly deaths, contrasting nursing home residents with all U.S. COVID-19 deaths, 2020-21. From the New York Times ©2021 The New York Times Company. All rights reserved. Used under license. page A1.85
all 50 states and U.S. territories numbered 606 million.\textsuperscript{97} Thus, through the FRPP alone, community pharmacists and their teammates delivered 45% of COVID-19 vaccinations across the United States, although that proportion has been higher or lower at specific points in time. For example, between April and July 2021, the proportion of vaccine doses distributed through states and other jurisdictions decreased from 62% in early April 2021 to 6% in mid-July 2021.\textsuperscript{84} During that same time, the proportion of vaccine doses distributed through the FRPP increased from 29% to 92%, according to a GAO analysis.\textsuperscript{83} The oft-quoted statistic of “more than 70% by pharmacists” was based on the Fall 2021 interval.

That 45% proportion for the FRPP does not include COVID-19 vaccinations conducted at the hands of pharmacists or under their direct supervision outside of the FRPPs.\textsuperscript{84,98-103} For example, at least 20 pharmacy chains took part in a state- or jurisdiction-level program for COVID-19 vaccination, typically focused on large and underserved populations.\textsuperscript{37} Other doses attributed to municipalities, states, or government agencies (e.g., VA, DoD, IHS) were administered by the hands of or at the direction of pharmacists. Pharmacists within health systems often led their institutions’ vaccination programs for workers and surrounding communities.\textsuperscript{100-105} Through August 22, 2021, CDC officials reported that pharmacists had administered 3,203,104 vaccine doses at 11,449 mobile clinics across the country.\textsuperscript{106} The additional doses represented by these and other efforts plausibly expand the proportion of pharmacist-directed COVID-19 vaccinations beyond 50% of the national total.

**Equity in vaccine distribution**

GAO analysis of FRPP data found that participating pharmacists fully vaccinated 51,554,294 people from February 11, 2021, through September 4, 2021.\textsuperscript{106} About 74% of those vaccination records contained information about race and ethnicity. Of those with documented race and ethnicity, 43% were from racial and ethnic groups other than non-Hispanic white. The GAO analysis suggests that pharmacists fully vaccinated a disproportionately greater share of non-Hispanic Asian and Hispanic or Latino persons. Non-Hispanic black and non-Hispanic white persons represented a slightly smaller share of persons fully vaccinated through pharmacists relative to their population shares.

The CDC uses several tools to assess the equity of COVID-19 vaccine distribution during the COVID-19 pandemic. The CDC calculates the social vulnerability index (SVI) at the county level based on data from the U.S. Census Bureau.\textsuperscript{107} Because there can be considerable heterogeneity within counties, the equitable distribution index (EDI) score assesses socioeconomic conditions more finely, at the zip-code level. The CDC’s analytical software anonymously records the EDI of the residence of people vaccinated against COVID-19 and the EDI of the location where they were vaccinated.

Pharmacists’ ability to equitably contribute to COVID-19 vaccine distribution can be assessed, in part, by considering the pharmacies in the Community Pharmacy Enhanced Services Network (CPESN) distributed across 46 States and the DC. These CPESN pharmacists and teammates administered 5.60 million doses as part of the FRPP between February 8, 2021, and June 8, 2022. Each of the 1961 participating CPESN pharmacies administered an average of 2856 vaccinations during this interval.\textsuperscript{108} CPESN FRPP unpublished data, June 8, 2022.

**Figure 2** compares the EDI of vaccine recipients’ residences to the EDI of the CPESN pharmacies for these 5.60 million vaccinations. The concordance of the 2 sets of bars shows that CPESN pharmacists vaccinated people who lived in settings with vulnerability indices similar to their pharmacy’s neighborhood. A similar high degree of concordance was also
apparent early in the vaccination program, from February 2021 through April 2021, when vaccine supplies were limited and concerns about equitable distribution were most acute (data not shown). The 1961 CPESN pharmacies include 1377 pharmacies (70.2%) sited in zip codes in the upper half of the EDI vulnerability range (i.e., EDI deciles 0.5 through 0.9), of which 942 (48.0%) are in the 3 highest deciles of vulnerability (i.e., 0.7 through 0.9). Of the 5.48 million vaccinations with a known pharmacy EDI, 67.9% were administered in pharmacies in the upper half of the EDI range and 40.9% with the EDI of 0.7 or greater. Of the 5.26 million vaccinations with a known recipient residence EDI, 67.1% were administered to people whose residence was in the upper half of the EDI range and 40.7% with the EDI of 0.7 or greater.

Pharmacists in all practice settings made countless contributions in explaining vaccines to the public, offering reassurance and reliable information from a trusted local source, while helping resolve uncertainty in the direction of accepting vaccination. A health equity report authored by National Association of Chain Drug Stores (NACDS) and the Johns Hopkins Center for Health Security noted the many ways pharmacists and pharmacies worked to enhance equity throughout the COVID-19 response and vaccination campaign: outreach to homebound individuals, pop-up clinics, partnerships with schools, community centers, places of worship, employers, community leaders, faith-based organizations, and organizations representing racial and ethnic minority groups. Pharmacies collaborated with rideshare companies, deployed mobile vaccination units, and went door to door through underserved communities. Community pharmacies helped address the needs of those with limited mobility, such as the elderly or people with disabilities. In multiple instances, people opted to receive their second COVID-19 vaccine dose from local, trusted, and easy-to-access community pharmacies, rather than returning to a mass-vaccination clinic or another venue.

The APhA posted dozens of video and print success stories of communications and vaccinations at its Vaccine Confident website (vaccineconfident.pharmacist.com), including at a Disneyland parking lot, at houses of worship, in multiple languages, and at centers serving the underserved. The American Society of Health-System Pharmacists, the American College of Clinical Pharmacy, and other organizations did likewise.

Between October 29, 2021, when the Pfizer-BioNTech pediatric COVID-19 vaccine received EUA status for children aged 5-11 years in the United States, and January 18, 2022, pharmacists and their teammates administered 46.4% of doses to this pediatric age group. This included 48.7% of doses in areas of high social vulnerability and 44.4% in low SVI areas. Pharmacy vaccine providers were permitted to bill COVID-19 vaccine administration fees for uninsured children to Medicaid rather than to the Vaccines for Children (VFC) program, which prevented unnecessary obstacles to care. CDC researchers noted, “Pharmacy providers were critical in addressing high initial demand for COVID-19 vaccine among this age group [i.e., 5-11 years old], including during evenings, weekends, and over holidays, when other providers might be less available.” Pharmacists also played a larger role in provision of COVID-19 vaccine to children aged 5-11 years compared with administration of routine vaccines: 46.4% of all COVID-19 pediatric vaccine doses were administered by pharmacy partners, whereas 12.3% of pediatric seasonal influenza vaccine doses were administered to children aged 5-12 years in pharmacies during 2020-21. Pharmacists are helping vaccinate children aged 6 months through 4 years now that vaccine is authorized for this age group.

A subsequent analysis of vaccine provider type between November 2021 and April 2022 found that 87.5% of U.S. counties had at least one active provider of COVID-19 vaccination for children 5 through 11 years of age, with pharmacies...
being the most common provider type (69.1%). The median number of pharmacy vaccine providers per county with a pharmacy provider was 3 (interquartile range: 1–8).

In June 2022, FDA expanded the EUAs for 2 COVID-19 vaccines to encompass young children 6 months and older. The ACIP and CDC likewise recommended their vaccination and pharmacists are now part of the effort to vaccinate that youngest cohort.

Examples of outreach

A CDC webpage lists examples of how pharmacists helped get America vaccinated against COVID-19 in February and March 2021 as the FRPP gained momentum. The Operation Immunization (August 2020 through June 2021), of Student Pharmacists (APhA-ASP) and the Student National

1. Jewel-Osco pharmacists’ teams administered 8600 COVID-19 vaccinations at more than 10 underserved sites in Chicago during a 10-day period.
2. Hague Pharmacy, a member of the CPESN, delivered 1300 vaccinations on a single day to African American residents of Norfolk’s Calvert Square neighborhood and another 1700 doses the following day in Chesapeake, VA.
3. Hy-Vee pharmacists vaccinated 1000 local Des Moines educators and staff on the Drake University campus.
4. Hy-Vee pharmacists also staffed mobile units to vaccinate staff at food-processing plants in Illinois and Iowa.
5. Meijer Pharmacy vaccinated 2600 educators at Ford Field in Detroit.
6. Giant Eagle Pharmacy vaccinated 4000 Pittsburghers at Heinz Field.
7. Walgreens pharmacists vaccinated 7000 people at a 3-day event held at 3 Atlanta Black Churches.
8. Walmart Pharmacies conducted 43 vaccination events at 79 locations in 18 states.

A team of 5 from Todd’s Drugs in Adamsville, Tennessee, vaccinated 100 residents of a remote and underserved town in a tent in a parking lot in less than 3 hours. The team returned several more times, administering more than 900 additional doses. Several “fearless pharmacy” stories from the Good Neighbor Pharmacy network are comparably compelling.

Since 1997, America’s student pharmacists have volunteered their extracurricular time to practice the clinical intricacies of vaccination in a program called “Operation Immunization,” a collaboration between the APhA’s Academy of Student Pharmacists (APhA-ASP) and the Student National Pharmaceutical Association. During the 2020-21 Operation Immunization Campaign (August 2020 through June 2021), the group reported that 13,884 student pharmacists, 1716 faculty mentors, and 2158 pharmacist preceptors collaborated to vaccinate 1,286,161 people (1,162,288 against COVID-19 and 82,318 against influenza). Several student chapters reported that their Operation Immunization activities were the only in-person activities they were permitted to hold.

One example involves the student pharmacists at the School of Pharmacy at the Notre Dame University of Maryland, based in Baltimore’s Blythewood neighborhood. The student pharmacists vaccinated at large community events on campus, with the Baltimore City Health Department, and at Safeway pharmacies serving the greater Baltimore region, providing more than 50,000 vaccinations. Further, these students provided thousands more vaccinations during more than 100 trials at 30 independent pharmacies in the metropolitan area. During initial shortages, they compounded alcohol-based sanitizers and led campus-wide mask-making efforts.

Vaccination against other vaccine-preventable diseases

According to CDC statistics, pharmacists administered 35.3 million doses of influenza vaccine to adults during the prepandemic 2019-20 season, increasing to 47.7 million in 2020-21 and softening to 40.5 million in 2021-22. In contrast, the CDC found that physician medical offices administered 36.8 million doses to adults in the prepandemic season, dropping to 32.8 million in 2020-21 and 30.9 million in 2021-22. Of those vaccinated against influenza in the 2020-21 season, about 39% of adults and 12% of children received their influenza vaccination from a community pharmacist.

A CDC report released in May 2020 found a troubling drop in routine childhood vaccination as families missed many in-person clinical visits early in the pandemic. This finding spurred the third amendment to the COVID-19 PREP Act Declaration (Table 1), preempting any state or local law that effectively prohibited pharmacists who satisfy federal requirements from distributing or administering COVID-19 vaccines, ACIP-recommended routine childhood vaccines, or COVID-19 tests as set forth above.

An analysis of noninfluenza vaccine-claim submissions were 13%-35% lower for adolescents and 17%-40% lower for adults in fall 2020, compared to the same period in 2019, suggesting that many people who should have received recommended vaccines in 2020 did not. This analysis found that adolescents and adults in the insurance cohorts studied missed an estimated 26 million doses of recommended vaccines from January to November 2020, compared to the same period in 2019.

The rationale for the preemption was the public health threat posed by the decrease in childhood-vaccination rates and the collateral harm caused by COVID-19. The DHHS actions cited the many states that already enable pharmacists to provide clinical services to children and established a uniform national scope of practice for qualified pharmacists. “Pharmacists are well positioned to increase access to vaccinations, particularly in certain areas or for certain populations that have too few pediatricians and other primary-care providers, or that are otherwise medically underserved. … Pharmacies often offer extended hours and added convenience. … Pharmacies also have strong relationships with local medical providers and hospitals to refer patients as appropriate.”

In October 2020, the CDC estimated that pharmacies represented 71 sites among 38,000 participating VFC providers. By May 2022, 135 pharmacies had status as VFC providers. (CDC unpublished data, May 16, 2022). Enrollment limitations and program requirements have constrained pharmacies’ ability or desire to enroll as VFC providers, to the detriment of vaccine coverage in vulnerable populations.

Antiviral prescribing and dispensing

On May 1, 2020, FDA issued an EUA for the antiviral drug remdesivir (Veklury, Gilead) to treat suspected or laboratory-confirmed COVID-19 in certain adults and children hospitalized with severe disease. It is administered by I.V. infusion.
As with other therapeutics first available during this pandemic, initial supplies were inadequate and pharmacists helped develop criteria for optimal use.128

The next big advance was the availability of oral antiviral medications.59 On December 22, 2021, FDA issued an EUA for Pfizer’s Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets). The next day, December 23, FDA issued an EUA for molnupiravir capsules (Lagevrio, Merck with Ridgeback Bio). These therapeutics involve the traditional paradigm of people being tested and treated by their own health care providers, who can prescribe these oral antivirals to eligible patients. Patients receive those prescriptions and counseling from their pharmacist.

Pharmacists have their usual pivotal role in the safe dispensing of these products, as they address safety considerations, drug interactions, patient education, handling, and reporting. Initially, the terms of the December 2021 EUAs issued by FDA for antivirals are more restrictive than the ninth (September 2021) amendment to the DHHS Secretary’s PREP Act Declaration (Table 1), making pharmacists ineligible to order or prescribe Paxlovid or molnupiravir except under state authorities for standing orders or collaborative practice agreements. The restrictions according to the December 2021 EUA wording restricted oral antiviral uptake, especially in communities of high social vulnerability.129,130 Even so, pharmacists generated awareness, answered patient questions, and assessed patients for eligibility after a confirmed COVID-19 infection, referring patients to their provider for a prescription.

Test-to-treat program

The federal test-to-treat program assembled a network of convenient-care clinics and adjacent pharmacists in March 2022 to help speed up access to antiviral medications.131,132 Under the structure of this federal program, when people tested positive at test-to-treat sites, they could get a prescription from an authorized health care provider and have the prescription filled at the adjacent pharmacy. People can also bring test results obtained from a home testing kit to test-to-treat sites and be evaluated by a health care provider for treatment. These one-stop test-to-treat sites are available nationwide at more than 2000 pharmacy-based clinics and Health Resources and Services Administration–supported federally qualified health centers.

According to a detailed analysis by the APhA,133 more than 28,000 community pharmacies were located in federally recognized underserved communities in May 2022, yet only 700 had test-to-treat sites. Capitalizing on the pharmacists in the underserved communities could increase access to COVID-19 treatment 39-fold. The least vulnerable areas nationwide host 78% of test-to-treat sites, whereas the most vulnerable communities have only 22% of these locations. These findings were confirmed by the CDC which found that “dispensing rates were lowest in high vulnerability zip codes, despite these zip codes having the largest number of dispensing sites.”134

Recognizing the benefits of improving COVID-19 antiviral access and equity, FDA amended the Paxlovid EUA on July 6, 2022, to allow skilled pharmacists with access to patient-specific information to order and prescribe this medication.135

Direct pharmacy distribution channel

From September 2021 through April 2022, the DHHS Office of the Assistant Secretary for Preparedness and Response used a state- and territory-coordinated distribution system for COVID-19 therapeutics.136 By April 2022, more than 500,000 courses of antivirals had been dispensed in the United States.137 Pfizer noted that prescriptions for Paxlovid in the United States increased from about 8000 patients per week in late February 2022 to nearly 80,000 patients for the week ending in April 22, 2022.138

On April 25, 2022, the DHHS transitioned to a new system that distributed antivirals directly through a pharmacy-specific distribution channel, rather than pharmacies receiving supplies from their state or jurisdiction.139 Expanded antiviral supply permitted expansion of the number of sites dispensing oral antiviral medications, increasing from 20,000 locations (e.g., pharmacies, community health centers, hospitals, urgent care centers, VA, and DoD facilities) in April 2022 toward a goal of 40,000 locations. Pharmacies continued to receive antivirals from state and territorial health departments and through the test-to-treat initiative.

Scope of practice and enabling authority

For pharmacists as skilled providers and pharmacies as centers of clinical care, the COVID–19 pandemic brought substantive expansions of authority. Expanded practice authority enabled that massive number of clinical interventions described above as well as their consistency from state to state. Clinical scopes of practice were standardized between states, bringing more expansive authority to pharmacists in some states. During the pandemic, pharmacists and pharmacists grew their collaborations with public health departments in depth and breadth across the country.137,140-144

Acting under authority of the PREP Act, the Secretary of the DHHS issued several declarations that preempted more restrictive professional authority at the state level for the duration of the COVID–19 pandemic (Table 1).133,134,135,136,137,143 Other expansions took the form of DHHS General Counsel advisory opinions and DHHS guidance documents. Many other countries did likewise.145 Pharmacists, student pharmacists (i.e., pharmacy interns), and pharmacy technicians nationwide received remarkable new authority, such as the following:

- Authorizing pharmacists, pharmacy interns, and pharmacy technicians to order or administer FDA-authorized COVID-19 tests
- Authorizing COVID-19 vaccination by pharmacists, pharmacy interns, and pharmacy technicians
- Authorizing any vaccination recommended for children 3 through 18 years old to be ordered and administered by pharmacists and to be administered by pharmacy interns
- Authorizing seasonal influenza vaccination by pharmacy interns and pharmacy technicians under the supervision of a pharmacist to persons aged 19 years and older consistent with ACIP recommendations
- Authorizing pharmacists to order and administer certain COVID-19 therapeutics (e.g., monoclonal antibodies) by injection or I.V. infusion and pharmacy interns and pharmacy technicians to administer these products.
In some cases, state regulatory changes will be needed to retain these practice authorities and their inherent public health value after the COVID-19 emergency ends or the authorities otherwise expire.142,144-146

Contributions of pharmacists internationally

Pharmacists around the world were entrusted with new clinical roles and responsibilities during the COVID-19 pandemic. Published reports describe enhanced authority to handle therapeutic interchange during medication shortages, offer public health services, treat minor ailments, authorize prescription renewals, provide COVID-19 and other testing services, facilitate clinical trials, minimize inappropriate antimicrobial prescribing, and more.37,145-158 Recognizing the public’s ease of access to a valuable care provider—their pharmacist—is a global phenomenon. The COVID-19 pandemic accelerated the trend since the 2000s for progressively more countries to train and authorize their pharmacists as vaccinators.147,153,159-163 In April 2022, Spain’s Ministry of Health awarded the Grand Cross of the Civil Order of Health, Spain’s highest distinction in the field of health, to the General Pharmaceutical Council of Spain for the pandemic contributions of Spain’s pharmacists.

Discussion

In the 1918-20 influenza pandemic, American pharmacists did what they could to help their patients, but there was little to offer beyond symptomatic relief.164 Viruses had not yet been identified; bacterial vaccines were ineffective at preventing influenza.2-4,164-169 Antipneumococcal sera had some effect in treating or preventing secondary pneumococcal infections.165,167 Disinfecting washes with various combinations of camphor, menthol, eucalyptus oil, phenol, and other components were popular, as were many patent medicines.168,170-172 The scarcity of sugar, due to the war effort, constrained the compounding of syrups.166 Treatments included acetylsalicylic acid for pain or fever, opiates for cough, and quinine, laxatives, and medicinal whiskey of dubious value.168,170,171

At this writing, in September 2022, the COVID-19 pandemic exceeds 2.5 years in duration, and we have had tools to prevent disease by vaccination for the last 22 months. Pharmacists and their teams provided pharmaceutical care in its many forms to more than 5.4 million COVID-19 infected patients hospitalized between March 2020 and September 2022.5,172,173 This analysis was limited in its ability to quantify pharmacists’ involvement with monoclonal-antibody and antiviral administration—an order-of-magnitude estimate would be a million patients. Numbers of vaccinations and COVID-19 tests are easier to quantify. Overall, pharmacists’ teams contributed more than 350 million interventions to more than 150 million individuals, despite supply constraints, intricate storage requirements, workflow revisions, and workforce shortages. These interventions were equitably distributed in communities with high social vulnerability.37,106,112 This report does not attempt to describe the many educational efforts conducted by pharmacists’ teams, neither individually nor collectively as organized into professional associations. These hundreds of millions of interventions came at a personal cost to the pharmacists and their teams: personal risk to their health in terms of a COVID-19 infection and an extraordinary increase in workload and stress.35,174,175

The Commonwealth Fund estimated that the U.S. national COVID-19 vaccination program had averted 2.2 million deaths, 17 million hospitalizations, 66 million infections, and $900 billion in health care costs between December 2020 and March 2022.176 The DHHS estimated that COVID-19 vaccinations among Medicare beneficiaries saved $2.6 billion from reduced hospitalizations in just the short interval from January through May 2021.177

What fraction of this human and economic value can be attributed to pharmacists and their teams? More detailed analysis is needed, but if pharmacists disproportionately reached seniors and the socially vulnerable who have borne the brunt of the pandemic, contributed 45% of all COVID-19 vaccinations via the community-pharmacy channel alone, as well as more vaccinations in other practice settings, pharmacists likely account for at least half of the harm averted and value gained. Pharmacy involvement in testing and monoclonal antibody and antiviral programs will have averted even more morbidity and mortality.

Pharmacists’ ability to provide essential services in pandemic response has been building from foundations laid more than 2 decades ago.75,129,140,141,144 The national movement to train pharmacists as vaccinators began in 1996 in Mississippi. Maine became the 50th state to authorize pharmacist-vaccinators in 2009. By the late 2010s, U.S. pharmacists delivered an estimated 50 million vaccinations each year.

During the 2009 influenza A/H1N1 pandemic response, the federal government leveraged the reach of 10 pharmacy chains to distribute 5.5 million doses of federally purchased vaccine among more than 10,700 community locations across the country, accounting for 23% of the vaccine distributed during that time period.73,74 In our 2020-22 COVID-19 experience, many more pharmacists over many more months administered almost 50 times that the number of COVID-19 vaccinations plus influenza and other vaccinations. And these numbers continue to rise as the pandemic continues.

In the mid-2010s, the CDC conducted exercises with pharmacists to assess their ability to provide vaccines and other countermeasures during a pandemic178 and recommended that state and local public health authorities actively collaborate with pharmacists to enable rapid vaccination of their populations.75-78,179 Although pharmacists were ultimately underutilized as pandemic vaccinators in 2009,74 that effort established the proof of concept and led to more robust planning efforts. Now, public health officials readily acknowledge the valuable contributions of pharmacists in population health and emergency preparedness.

Even with the prepandemic planning and multiple 2020-21 planning meetings,179 actual implementation in December 2020 and early 2021 was hectic, stressful, and yet intensely rewarding to the pharmacists’ teams that participated.16,14 Each of the national and state associations of pharmacists devoted innumerable hours to programming, sharing ideas, and supporting their members. Once each of the teams completed its own local learning curve, pharmacists reported that they had more capacity to vaccinate than they had doses to administer.27,86
Curiously, pharmacists administered a greater proportion of pediatric COVID-19 vaccinations than of pediatric influenza vaccinations.\textsuperscript{117} Future research could assess the relative contributions of proximity of pharmacists in settings of elevated social vulnerability, willingness or reluctance of other professions or practice settings to offer vaccination, and other factors contributing to the differential.

The advantages pharmacists offer in providing clinical interventions around several key parameters are as follows:

- **Clinical competence:** Extensive knowledge- and skills-based experience
- **Convenient access:** 90\% of Americans live within 5 miles of a community pharmacy,\textsuperscript{27-40} offering extended hours of availability
- **Trust:** established relationships with their patients, reaching into underserved communities
- **Networked professionals:** Pharmacists embedded within collaborative networks of other medical providers that readily share detailed clinical information, both in community pharmacy settings and as members of patient care teams in hospitals and health systems

NACDS issued an interim evaluation of successes and lessons learned in COVID-19 intervention programs in November 2021.\textsuperscript{37} Additional thoughtful, candid reviews of what worked and what did not (and how to preclude problems during the inevitable next pandemic) will be needed.

The NACDS lessons-learned report identified a key point: the (for some, recently recognized) value of pharmacists networking with public health departments.\textsuperscript{27}

"... in one national survey of pharmacists conducted in 2012, over two-thirds of pharmacists polled had no contact with a state or local public health official in the past year.\textsuperscript{183} In stark contrast, [NACDS Virtual] Forum participants frequently mentioned that establishing and reinforcing partnerships with state and local public health was a major success factor that will yield benefits beyond the current pandemic. One Forum participant mentioned ‘this was really our first connection with our state Department of Health.’ Several Forum participants noted that it was the first time that public health officials ‘saw what we could do to improve public health. Public health folks are now advocating for what pharmacy used to have to solely advocate for.’ Another commented that ‘this [partnership] gave pharmacy [better ability to collaborate with public health] to pinpoint where there are pockets of needs for vaccine services—this can be grown potentially for other clinical services in future.’

The successes from the COVID-19 interventions described in this report show how pharmacists and their teammates played vital roles as health care providers during a public health crisis. These competencies and capacities can be applied in more normal times to improve health care access and strengthen community health nationwide.\textsuperscript{129,142,144,184} It will be important for communities to maintain their access to the care of a pharmacist they have come to expect and depend on during the pandemic. Therefore, it is essential to ensure that the scope-of-practice standardizations and sustainability mechanisms that increased the provision of pharmacist services during the pandemic remain in place and are enhanced after the pandemic subsides.

When the final tally of COVID-19 interventions is compiled, pharmacists will be justly recognized for the quality and magnitude of their contributions as care providers who mitigated and eventually controlled this pandemic. The tally in aggregate will show the pharmacist’s value in a programmatic and economic sense, but its most meaningful benefit will manifest in the health of individual neighbors cared for one by one.\textsuperscript{3}

**Document your contributions**

This report features a small fraction of the ways pharmacists provided care for their communities. Record your contributions and those of your institution, association, or state. The American Institute of the History of Pharmacy (AIHP) invites contributions to its COVID-19 Pandemic Pharmacy Historical Documentation Project (https://aihp.org/collections/aihp-covid19-project/), to preserve pharmacists’ experiences during the pandemic. The AIHP seeks stories, photos, videos, artifacts, and other documentation of the COVID-19 pandemic’s effects on society.

**Conclusion**

Pharmacists and their teammates contributed essential services to America’s health and recovery during the COVID-19 pandemic as providers of multiple hundreds of millions of clinical interventions to hundreds of millions of people. Pharmacy teams responded quickly and courageously to rapidly changing circumstances, providing personalized care despite risks to their own health from the highly contagious virus. Despite medication shortages, supply shortages, and staffing shortages, pharmacists overcame geographic and cultural distances to provide compassionate care in every pharmacy practice setting.

**Dedication**

This report is dedicated to the pharmacists and their teammates who persevered in spring 2020, when little was known and much was feared.

**Acknowledgments**

Recognizing their input, advice, and critique: Nancy A. Alvarez, Scott J. Bergman, Lynette R. Bradley-Baker, Monali Bhosle, Anne Burns, Cody L. Cifton, Kimberly S. Crole, Arthur Daemmrich, Sharon G. Humiston, Christopher John, Lisa M. Koonin, Anne Lin, Michael S. Maddux, Lucinda L. Maine, Eric M. Maroyka, Erin K. McCreary, Sara R. Roszak, Mitchel C. Rothholz, Douglas J. Scheckelhoff, Jann B. Skelton, Gonçalo Sousa Pinto, Alli Jo Shipman, Catherine A. Taglieri, Theresa Taylor, Troy Trygstad, Dennis B. Worthen, and William A. Zellmer.
References

1. Wikipedia. COVID-19 pandemic in the United States. Available at: https://en.wikipedia.org/wiki/COVID-19_pandemic_in_the_United_States. Accessed July 12, 2022.

2. Crosby AW. America’s Forgotten Pandemic: the Influenza of 1918. New York, NY: Cambridge University Press; 1989.

3. Kola G. Flu: the story of the Great Influenza Pandemic of 1918 and the Search for the Virus That Caused It. New York, NY: Farrar Straus Giroux; 1999.

4. Barry JM. The Great Influenza: the epic story of the deadliest plague in History. New York, NY: Viking Adult; 2004.

5. Centers for Disease Control & Prevention. COVID-19 data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#/data-tracker. Accessed September 14, 2022.

6. Grabenstein JD, Rochetti Honor Medal Address: The Patients (the People) You Touch. J Am Pharm Assoc (2003). 2020;60(5):e1–e4.

7. Grabenstein JD. Vaccine immunity. J Am Pharm Assoc (2003). 2022;62(1): 286–287 (editorial).

8. Hogue MD. You are heroes. J Am Pharm Assoc (2003). 2021;61(4): e10–e11.

9. Abdul-Mutalab JJ, Casey S, Jewis V, et al. A three-tiered approach to address barriers to COVID-19 vaccine delivery in the Black community. J Am Healthc Healthc. 2021;19(5):e749–e750.

10. IQVIA Institute for Human Data Science. The use of medicines in the U.S.: spending and usage trends and outlook to 2025. IQVIA. Available at: www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us-2019-to-2025-white-paper.pdf. Accessed July 12, 2022.

11. American Hospital Association. Fast facts on US hospitals. Available at: www.aha.org/system/files/media/file/2021/01/Fast-Facts-2021-table-FY19-data-14jan21.pdf. 2021. Accessed July 12, 2022.

12. Harris-Kojetin L, Sengupta M, Lendon JP, Rome V, Valverde R, Caffrey C. Pharmacists: front line in the emergency preparedness response during the COVID-19 pandemic and beyond. Res Social Adm Pharm. 2021;17(1):980–1912.

13. Herzik KA, Bethishou L. The impact of COVID-19 on pharmacy transitions of care services. Res Soc Adm Pharm. 2021;17(1):1908–1912.

14. Aruru M, Truong HA, Clark S. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals’ roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res Soc Adm Pharm. 2021;17(1):1967–1977.

15. Strand MA, Bratberg J, Eukel H, Hardy M, Williams C. Community pharmacists’ contributions to disease management during the COVID-19 pandemic. Prev Chronic Dis. 2020;17:E59.

16. Johnston K, O’Reilly CL, Cooper G, Mitchell I. The burden of COVID-19 on pharmacists. J Am Pharm Assoc (2003). 2021;61(2):e61–e64.

17. American College of Clinical Pharmacy. Clinical pharmacy in action: ACCP members respond to the COVID-19 pandemic. Available at: www.accp.com/member/clinicalpharmacyinaction/COVID-19.aspx. Accessed July 12, 2022.

18. MaArthur RB, Bentur OS, MacArthur IC, et al. CTSA pharmacies: the pharmacist role in SARS-CoV-2 diagnostic testing. J Am Pharm Assoc (2003). 2022;62(1):725.

19. Do T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse. Infect Dis Ther. 2020;9(1):561–572.

20. Pedersen CA, Schneider PJ, Ganoic MC, Sheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: impact of COVID-19 pandemic on pharmacy operations—2020. J Am Health Syst Pharm. 2021;78(11):1701–1711.

21. Warr D, Storey E, Denys M, Brown S, Rose C. Providing pharmacy services in a basketball arena: reflections on building a pharmacy in a COVID-19 surge facility. J Am Health Syst Pharm. 2021;78(5):416–425.

22. Lee M, Razaki H, Mui V, Rao P, Brocavich S. The pivotal role of pharmacists during the 2019 coronavirus pandemic. J Am Pharm Assoc (2003). 2020;60(6):e73–e75.

23. American Society of Consultant Pharmacists. Field guide to reduce medication burden during COVID-19. Available at: www.ascp.com/resource/resmgr/docs/disaster/field_guide_to_reduce_medica.pdf. Accessed July 12, 2022.

24. American Society of Consultant Pharmacists. Timeline of HHS regulations and legislative activities relating to the COVID-19 pandemic and pharmacy. Available at: www.ascp.com/resource/resmgr/docs/disaster/league_of_hhs_regulations.pdf. Accessed September 14, 2022.

25. Mun F, Hale CM, Henriksen EK. A survey of US hospitals’ criteria for the allocation of remdesivir to treat COVID-19. Am J Health Syst Pharm. 2021;78(3):235–241.

26. Traynor K. Pharmacist-managed triage service guides COVID-19 anti-viral treatments. Am J Health Syst Pharm. 2022;79(9):e699.

27. Congressional Research Service. COVID-19 testing: frequently asked questions. Available at: https://crsreports.congress.gov/product/pdf/R/ RL36481; 2021. Accessed September 14, 2022.

28. Food & Drug Administration. Coronavirus disease 2019 (COVID-19) emergency use authorizations for medical devices. Available at: www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices. Accessed September 14, 2022.

29. National Association of Chain Drug Stores. Community retail pharmacies’ experience during the COVID-19 response: successes and lessons learned to date. Available at: www.nacds.org/pdfs/pharmacy/2021/Commu_nityRetailPharmaciesExperience-during-the-COVID-19-Response-Successes-and-Lessons-Learned-to-Date.pdf. 2022. Accessed July 12, 2022.

30. Chevalier JA, Schwartz JL, Su Y, Williams KR. Distributional impacts of retail vaccine availability. J Urban Econ. 2022;127:103382.

31. National Association of Chain Drug Stores. Face-to-face with community pharmacies. Available at: www.nacds.org/pdfs/about/rxingimpact/severebehind.pdf. 2022. Accessed July 12, 2022.

32. Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007–2015. PLoS One. 2017;12(8):e0183172.

33. Mun F, Hale CM, Henriksen EK. A survey of US hospitals’ criteria for the allocation of remdesivir to treat COVID-19. Am J Health Syst Pharm. 2021;78(3):235–241.

34. National Alliance of State Pharmacy Associations. COVID-19: federal PREP act actions. Available at: https://naspa.us/resource/federal-prep-acts/. Accessed July 12, 2022.

35. Goode JR, Page A, Burns A, Bernard S, Wheawill S, Gatewood SBS. The pharmacist’s role in SARS-CoV-2 diagnostic testing. J Am Pharm Assoc (2003). 2020;60(6):e19–e32.

36. O’Connor SK, Healy R, Mark N, Adams JL, Robinson R, Nguyen E. Developing sustainable workflows for community pharmacy–based SARS-CoV-2 testing. J Am Pharm Assoc (2003). 2022;62(1):253–259.

37. Federal Emergency Management Agency. By the numbers – coronavirus pandemic whole-of-America response. Available at: https://content.govdelivery.com/attachments/USDHSFEMA/2021/03/09/file_attachments/1717220/Bys%20the%20Numbers.COVID.FINAL.pdf. 2021. Accessed July 12, 2022.

38. U.S. Department of Health & Human Services. HHS continues community-based testing sites for COVID-19. Available at: www.hhs.gov/about/news/2021/01/07/hhs-continues-community-based-testing-sites-covid-19.html. Accessed July 12, 2022.

39. Centers for Disease Control & Prevention. Increasing community access to testing (ICATT) for COVID-19. Available at: www.cdc.gov/icatt/index.html; 2022. Accessed July 14, 2022.

40. Patel J, Christopherson N, Goodlett KJ. Pharmacist-provided SARS-CoV-2 testing targeting a majority-Hispanic community during the early
COVID-19 pandemic: results of a patient perception survey. J Am Pharm Assoc (2002). 2022;62(1):187–193.

49. Casadevall A, Dadachova E, Pirosfai L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695–703.

50. Block EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765.

51. Focosi D, Franchini M, Pirosfai LA, et al. COVID-19 convalescent plasma is more than neutralizing antibodies: a narrative review of potential beneficial and detrimental co-factors. Viruses. 2021;13(6):1594.

52. Rogers A. 97,000 people got convalescent plasma. Who knows if it works? Wired. Available at: www.wired.com/story/97000-people-got-convalescent-plasma-who-knows-if-it-works/; 2020. Accessed July 12, 2022.

53. Blackall D, Wulf S, Roettger T, et al. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network. Transfusion. 2020;60(10):2203–2209.

54. Drug Information Group, University of Illinois College of Pharmacy. Update: what do pharmacists need to know about convalescent plasma for COVID-19. Available at: https://dig.pharmacy.uiuc.edu/faqs/2021-2/february-2021-faqs-update-what-do-pharmacists-need-to-know-about-convalescent-plasma-for-covid-19/; 2021. Accessed July 12, 2022.

55. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma infusion on the duration of hospitalization of patients with severe COVID-19. Vaccine. 2021;39(7):1629–1635.

56. Koonin LM, Beauvais DR, Shimabukuro T, et al. CDC COVID-19 vaccine initiative in the United States: implications for future public health and pharmacy collaborations for emergency response. Disaster Med Public Health Prep. 2021;15(5):797–807.

57. Rubin SE, Schulman RM, Roszak AR, Herrmann J, Patel A, Koonin LM. Leveraging partnerships among community pharmacists, pharmacies, and health departments to improve pandemic influenza response. Biosecur Bioterror. 2014;12(2):137–142.

58. Centers for Disease Control & Prevention. Public health emergency preparedness and response capabilities: national standards for state, local, tribal, and territorial public health. Available at: www.cdc.gov/npip/reports/readiness/responsecapabilities/; 2021. Accessed September 14, 2022.

59. Estcourt L, Callum J. Convalescent plasma for Covid-19. Nat Rev Microbiol. 2021;19(8):453.

60. McCreary EK, Bariola JR, Wadas RJ, et al. Association of subcutaneous or IV administration of the bamlanivimab; 2021. Accessed July 12, 2022.

61. Malashock C, Keifer A, Reisbig K, Reha C, Alexander BT. Pharmacist role in advancing access to COVID-19 countermeasures, including vaccine distribution and communication efforts should include stakeholder perspectives. Available at: www.gao.gov/assets/gao-21-402t.pdf; 2021. Accessed September 14, 2022.

62. Traynor K. Pharmacists fill caregiver gaps to expand COVID-19 antibody therapy. Available at: www.pharmacist.com/overview-of-barriers-and-facilitators-in-covid-19-vaccine-administration. Accessed September 14, 2022.

63. Schwerzmann J, Graitcer SB, Jester B, et al. Evaluating the impact of pharmacists on vaccine administration. Disaster Med Public Health Prep. 2021;7(11):587–593.

64. University of Pittsburgh Medical Center. When demand outstrips capacity, injections of Covid-19 treatment instead of IV are justified. Available at: www.upmc.com/media/news/120221-mccreasy-kip-subq-mabs/; 2021. Accessed July 12, 2022.

65. U.S. Department of Health and Human Services. Public readiness and emergency preparedness act and its amendments: COVID-19 PREP act. Available at: www.gao.gov/assets/720000/gao-22-104457.pdf; 2021. Accessed September 14, 2022.

66. Conlen M, Mervosh S, Ivory D. Nursing homes, once hot spots, now face much more success. January 25, 2021. Brookings Institution, Washington, DC. Available at: https://aspe.hhs.gov/reports/covid-19-vaccine-outreach; 2021. Accessed July 12, 2022.

67. Gonzales A, Lee EC, Grigorescu V, Smith SR, De Lew N, Sommers BD. Overview of barriers and facilitators in COVID-19 vaccine outreach. Available at: https://aspe.hhs.gov/reports/covid-19-vaccine-outreach; 2021. Accessed July 12, 2022.

68. Galston WA. COVID-19 vaccines: why are some states and localities so much more successful? January 25, 2021. Brookings Institution, Washington, DC. Available at: www.brookings.edu/blog/fixgov/2021/01/25/covid-19-vaccinations-why-are-some-states-and-localities-so-much-more-successful/; 2021. Accessed July 12, 2022.

69. Rafa M. Pharmacists answer the call for COVID-19 vaccine administration. West Virginia Pharmacists Association. Available at: https://wvpharmacy.org/2020/12/pharmacistanswercall/; 2020. Accessed July 12, 2022.

70. Wharton O. What the world can learn from West Virginia’s successful vaccine rollout: in the race to vaccinate, the state’s personal touch is a winner. National Geographic. Available at: www.nationalgeographic.com/culture/
101. Gregory N. Pharmacy leadership, expertise imperative for successful vaccine-rollout; 2021. Accessed September 14, 2022.

102. Dunn L, Beck C. Pharmacists say ‘pooling’ Covid vaccines could save thousands of doses. Available at: www.nbcnews.com/health/health-news/pharmacists-say-pooling-covid-vaccines-could-save-thousands-of-doses-n1258149; 2021. Accessed July 12, 2022.

103. Allen A. To extract more doses per vial, vaccinators put squeeze on FDA to relax vaccine handling advice. Kaiser Health News. Available at: https://vaccinecon.com/2021-extract-more-doses-vials-vaccinators-put-squeeze-fda-relax-vaccine-handling-advice; 2021. Accessed July 12, 2022.

104. Traynor K. Children’s hospital celebrates successful COVID-19 vaccine rollout. Am J Health Syst Pharm. 2021;78(10):838–839.

105. Centers for Disease Control & Prevention. COVID-19 vaccine access in long-term care settings. Available at: www.cdc.gov/vaccines/COVID-19-long-term-care/pharmacy-partnerships.html; 2022. Accessed July 12, 2022.

106. Gregory N. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout. Am J Health Syst Pharm. 2021;78(14):1264–1266.

107. Gregory N. COVID-19 vaccines in tribal communities save lives, preserve culture. Am J Health Syst Pharm. 2021;78(10):835–839.

108. Traynor K. Health systems quickly vaccinated communities against COVID-19 despite supply constraints. Am J Health Syst Pharm. 2021;78(11):940–942.

109. Centers for Disease Control & Prevention. COVID-19 vaccinations in the United States. Available at: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total. Accessed September 14, 2022.

110. Traynor K. COVID-19 mass vaccination involves unusual venues. Am J Health Syst Pharm. 2021;78(13):1162–1164.

111. Gregory N. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout. Am J Health Syst Pharm. 2021;78(14):1264–1266.

112. Tran W, Shaw M, DeAngelis J, et al. Implementation of a pharmacist-led COVID-19 vaccination clinic at a community teaching hospital. Am J Health Syst Pharm. 2021;78(12):1038–1042.

113. Federal Emergency Management Agency. Community vaccination centers playbook. Available at: www.fema.gov/disaster/coronavirus/government/community-vaccination-centers-playbook; 2021. Accessed July 12, 2022.

114. Traynor K. COVID-19 mass vaccination involves unusual venues. Am J Health Syst Pharm. 2021;78(13):1162–1164.

115. American Society of Health-System Pharmacists. Pharmacy on the front lines of the COVID-19 pandemic. Available at: www.ashp.org/covid-19-stories; 2021. Accessed July 12, 2022.

116. AmerisourceBergen Corporation. Fearless pharmacy: good neighbor pharmacy stores administering COVID-19 vaccinations. Available at: www.amerisource.com/fearless-pharmacy; 2021. Accessed July 12, 2022.

117. Kim C, Yee R, Bhatkoti R, et al. COVID-19 vaccine provider access and vaccination coverage among children aged 5–11 years—United States, November 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:378–383.

118. DeCuir J, Meng L, Pan Y, et al. COVID-19 vaccine provider availability and vaccination coverage among children aged 5–11 years — United States, November 1, 2021–April 25, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:847–850.

119. McKesson Corporation. Rural pharmacies providing COVID-19 vaccinations: select U.S. health mart pharmacies have started vaccinating patients. Available at: www.mckesson.com/Our-Stories/Rural-Pharmacies-Providing-COVID-19-Vaccinations; 2022. Accessed July 12, 2022.

120. American Pharmacists Association—Academy of Student Pharmacists. Operation immunization annual report, 2020-2021. American Pharmacists Association; 2022. Washington, DC.

121. Notre Dame of Maryland University. School of pharmacy dean named health care hero by The Daily Record. Available at: www.ndmu.edu/news-and-events/news/school-pharmacy-dean-named-health-care-hero-daily-record; 2022. Accessed July 12, 2022.

122. Centers for Disease Control & Prevention. Influenza vaccinations administered in pharmacies and physician medical offices, adults, United States. Available at: www.cdc.gov/vaccines/state/flu-vaccines/pharmacy-influenza-vaccination-administered.html; 2022. Accessed July 12, 2022.

123. Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:591–593.

124. U.S. Department of Health & Human Services. Third amendment to COVID-19 PREP Act declaration—childhood vaccines, August 24, 2020. Washington, DC. Available at: www.hhs.gov/sites/default/files/third-amendment-declaration.pdf; 2022. Accessed July 12, 2022.

125. Lowy C, Gillen EM, Becker L, Trost A, Young J. Updated analysis finds sustained drop in routine vaccines through 2020. Available at: https://avacere.org/insights/updated-analysis-finds-sustained-drop-in-routine-vaccines-through-2020/2022; 2021. Accessed July 12, 2022.

126. Association of State & Territorial Health Officials. Key considerations for pharmacies and the vaccines for children (VFC) program; summary of interview and survey findings. Available at: www.mysocietysource.org/sites/HPV/ResourcesandEducation/Lists/Clearinghouse/Attachments/516/ASTHO%20VFC%20Pharmacy%20Report_Executive%20Summary.pdf; 2015. Accessed July 12, 2022.

127. Rodriguez CH. Feds look to boost childhood immunization rates. Kaiser Health News. Available at: https://khn.org/news/pharmacist-federal-training-program-perform-vaccinations-to-boost-childhood-immunization-2022/2022. Accessed July 12, 2022.

128. Fox ER, Shah M, Vinik R, et al. Developing statewide remdesivir use criteria. Am J Health Syst Pharm. 2021;78(8):732–735.

129. Abramowitz PW, Thompson KK, Cobaugh DJ. Pharmacists: essential providers of COVID-19 care. Am J Health Syst Pharm. 2022;79:927–928.

130. Abraham ME, Mutabak A, Brown ML, et al. Convene state health agencies to identify early vaccination targets for initiatives that increase equitable access to COVID-19 therapeutics. Lancet Reg Health Am. 2022;11:100263.

131. U.S. Department of Health & Human Services. Test-to-treat. Available at: https://aspr.hhs.gov/TestToTreat/Pages/default.aspx. Accessed July 12, 2022.

132. Weiland N. With supply more abundant, pharmacies struggle to use up Covid pills. NY Times. Available at:www.nytimes.com/live/2022/04/26/world/mandates-cases-vaccine-covid-19#paxlovid-test-to-treat; 2022. Accessed July 12, 2022.

133. American Pharmacists Association. Inequity to COVID-19 test to treat access—pharmacists can help if permitted. Available at: www.pharmacist.com/Advocacy/Issues/Inequity-to-COVID-19-Test-to-Treat—Access-Pharmacists-can-help-if-permitted; 2022. Accessed July 12, 2022.

134. Gold JAW, Kelleher J, Magid J, et al. Dispensing of oral antiviral drugs for COVID-19: federal efforts to provide access. U.S. Department of Health & Human Services. State/territory-coordinating council for the national drug distribution of COVID-19 therapeutics. Available at: https://aspr.unm.edu/operation/2022/03/021.

135. Weiland N. With supply more abundant, pharmacies struggle to use up Covid pills. NY Times. Available at:www.nytimes.com/live/2022/04/26/world/mandates-cases-vaccine-covid-19#paxlovid-test-to-treat; 2022. Accessed July 12, 2022.

136. U.S. Department of Health & Human Services. Test-to-treat. Available at: https://aspr.hhs.gov/TestToTreat/Pages/default.aspx. Accessed July 12, 2022.
182. Gessler CA, Richardson RM, Hall DL, Coley KC. Operationalizing pandemic vaccinations at a regional supermarket chain pharmacy. *Disaster Med Public Health Prep*. 2021;1:1–6.

183. Steelfisher GK, Benson JM, Caporello H, et al. Pharmacist views on alternative methods for antiviral distribution and dispensing during an influenza pandemic. *Health Secur*. 2018;16(2):108–118.

184. Ashcraft AM, Ponte CD, Farjo S, Dotson S, Murray PJ. The [underutilized] power of independent pharmacies to promote public health in rural communities: a call to action. *J Am Pharm Assoc (2003)*. 2022;62(1):38–41.

John D. Grabenstein, RPh, PhD, FAPhA, FASHP. Vaccine Dynamics, Easton, MD
Supplementary appendix to the article

Main Points:

> **270 million** COVID-19 vaccinations given by community pharmacists and teams, December 2020-September 2022\(^\text{84,96,97}\)

> **45%** of U.S. COVID-19 vaccinations given by community pharmacists and teams, December 2020-September 2022\(^\text{96,97}\)

> **50%** of U.S. COVID-19 vaccinations overall given via pharmacist-led programs, December 2020-September 2022\(^\text{84,96,97-103,104-106}\)

> **8.1 million** COVID-19 vaccinations given by pharmacists and teams at long-term care (LTC) facilities, December 2020-April 2021\(^\text{84,96,97}\)

> **2/3 drop** in COVID-19 deaths among LTC residents fell by two-thirds compared to all COVID-19 deaths, December 2020-February 2021\(^\text{85}\)

> **1.3 million** vaccinations given by student pharmacists via "Operation Immunization," December 2020-June 2021\(^\text{120}\)

> **42 million** patient specimens tested by pharmacists for COVID-19, April 2020-July 2022\(^\text{37,43,45-47}\)

Secondary Points:

> **100,000** COVID-19 monoclonal antibody treatments provided by pharmacists, November 2020-June 2022

> **70%** of vaccinating pharmacies located in communities with moderate-to-high social vulnerability\(^\text{77}\)

> **12 million** more influenza vaccinations given by pharmacists to adults in 2020-21 season compared to previous season (47.7 million vs. 35.3 million for 2019-20)\(^\text{122}\)

> **# 1** West Virginia was the first state to offer COVID-19 vaccination to all LTC residents: pharmacists from 250 community pharmacies gave 28,000 vaccinations in 210 LTC facilities\(^\text{86-90,91}\)

> **5.4 million inpatients** cared for by pharmacists and teams, February 2020-September 2022\(^\text{5,172,173}\)

> **350 million interventions**

> **150 million individuals** received COVID-19 care provided by a pharmacist